Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

MULTIPLE SCLEROSIS

MRI predicts cognitive training effects in multiple sclerosis

Cognitive rehabilitation is a promising approach to limit the effect of cognitive impairment on patients with multiple sclerosis, although results so far are conflicting. A new study indicates that structural and functional MRI techniques could provide reliable measures to predict treatment responses and tailor the rehabilitative approach to each patient.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. DeLuca, J., Chiaravalloti, N. D. & Sandroff, B. M. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat. Rev. Neurol. 16, 319–332 (2020).

    Article  Google Scholar 

  2. Chen, M. H., Goverover, Y., Genova, H. M. & DeLuca, J. Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review. CNS Drugs 34, 599–628 (2020).

    Article  Google Scholar 

  3. Preziosa, P., Conti, L., Rocca, M. A. & Filippi, M. Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity. J. Neurol. 269, 1052–1064 (2022).

    Article  Google Scholar 

  4. Goverover, Y., Chiaravalloti, N. D., O’Brien, A. R. & DeLuca, J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: an updated review of the literature from 2007 to 2016. Arch. Phys. Med. Rehabil. 99, 390–407 (2018).

    Article  Google Scholar 

  5. Rocca, M. A., Preziosa, P. & Filippi, M. Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. Expert Rev. Neurother. 19, 835–866 (2019).

    CAS  Article  Google Scholar 

  6. Lampit, A. et al. Computerized cognitive training in multiple sclerosis: a systematic review and meta-analysis. Neurorehabil. Neural Repair 33, 695–706 (2019).

    Article  Google Scholar 

  7. Prouskas, S. E. et al. A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: is there a window of opportunity? Mult. Scler. https://doi.org/10.1177/13524585221103134 (2022).

    Article  PubMed  Google Scholar 

  8. Rocca, M. A. et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 74, 1252–1259 (2010).

    CAS  Article  Google Scholar 

  9. Eijlers, A. J. C. et al. Reduced network dynamics on functional MRI signals cognitive impairment in multiple sclerosis. Radiology 292, 449–457 (2019).

    Article  Google Scholar 

  10. Fuchs, T. A. et al. Functional connectivity and structural disruption in the default-mode network predicts cognitive rehabilitation outcomes in multiple sclerosis. J. Neuroimaging 30, 523–530 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Competing interests

M.F. is editor-in-chief of the Journal of Neurology, associate editor of Human Brain Mapping, associate editor of Radiology and associate editor of Neurological Sciences. He has received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche and Sanofi, and for speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Roche, Sanofi, Takeda and TEVA. He has participated on advisory boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme and Takeda, and has been a scientific director for educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis and Sanofi-Genzyme. He receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARiSLA (Fondazione Italiana di Ricerca per la SLA). P.P. has received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb and Genzyme. He has received research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Filippi, M., Preziosa, P. MRI predicts cognitive training effects in multiple sclerosis. Nat Rev Neurol 18, 511–512 (2022). https://doi.org/10.1038/s41582-022-00701-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-022-00701-1

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing